Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical
challenges due to their invasive nature and limited treatment options. The current …

Glioblastoma (GBM) treatment is still a big clinical challenge because of its highly malignant,
invasive, and lethal characteristics. After treatment with the conventional therapeutic …

Cancer theragnostics is a novel approach that combines diagnostic imaging and
radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized …

Extracellular vesicles (EVs) produced by various immune cells, including B and T cells,
macrophages, dendritic cells (DCs), natural killer (NK) cells, and mast cells, mediate …

Glioblastoma multiforme (GBM) is a malignancy of bad prognosis, and advances in early
detection and treatment are needed. GBM is heterogenous, with varieties differing in …

Glioblastoma (GB) is a rare but extremely aggressive brain tumor that significantly impacts
patient outcomes, affecting both duration and quality of life. The protocol established by …

During the last 20 years, molecular alterations have gained increasing significance in the
diagnosis and biological assessment of tumors. Gliomas represent the largest group of …

Immunotherapy is regarded as one of the most promising approaches for treating tumors,
with a multitude of immunotherapeutic thoughts currently under consideration for the lethal …

Gliomas are common central nervous system (CNS) tumors that are classified according to
morphology and molecular characteristics, graded according to malignancy. The World …

Glioblastoma, an aggressive primary brain tumor, poses a significant challenge owing to its
dynamic and intricate tumor microenvironment. This review investigates the innovative …